With six approved drugs, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA®, ADCETRIS® and over 300 drugs underdevelopment, antibody drug conjugates (ADCs) have emerged as a promising class of targeted therapies for various disease indications.   London   Roots Analysis has announced the addition of “ADC Payloads Market, 2021-2030”...